Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?

Abstract

Coronary stenting in acute coronary syndromes probably increases the risk of acute stent thrombosis. Recently, use of platelet glycoprotein IIb/IIIa receptor antibody has been shown to improve percutaneous transluminal coronary angioplasty (PTCA) outcomes in high risk lesions. The purpose of this analysis was to determine safety and efficacy of platelet glycoprotein IIb/IIIa receptor antibody administration in patients receiving coronary stents in high‐risk lesions. Between October 1995 and November 1996, 282 patients with acute ischemic syndromes received coronary stents at our center: 73 had thrombus containing lesions—40 presented with AMI and 33 with unstable angina and make up the study population. The mean age of these patients was 61 ± 13 years, 56 were male, 35 had a history of myocardial infarctions (MI), 21 had prior coronary artery bypass graft (CABG), and 21 had prior PTCA. Coronary stenting was used for suboptimal result in 46 patients (63%), threatened closure in 25 patients (34%), and acute closure in 2 patients (3%). Platelet glycoprotein IIb/IIIa receptor antibody was administered during the procedure in 74% and after the procedure in 26%. A total of 115 stents were deployed (Gianturco‐Roubin 80, Palmaz‐Schatz 29, and Wallstent 6) in 24 LAD, 21 RCA, 15 LCX, and 13 saphenous vein graft (SVG) lesions. Procedural success was 100%. The mean diameter stenosis before and after intervention was 60% ± 31% and 4% ± 14%, respectively. In‐hospital events included 1 Q‐wave MI (1.4%), 13 non–Q‐wave MI (18%), and 1 death (1.4%). There was no subacute stent thrombosis, emergency CABG, or repeat PTCA. Significant in‐hospital bleeding complications were noted in seven (10%) patients, with five patients (6.8%) requiring blood transfusions. In this series of patients with acute ischemic syndromes associated with angiographic evidence of thrombus, combined use of platelet glycoprotein IIb/IIIa receptor antibody and stenting resulted in a very low incidence of subacute stent thrombosis and emergency target lesion revascularization. However, bleeding complications were higher than expected with conventional antiplatelet therapy following routine stenting. Cathet. Cardiovasc. Intervent. 46:415–420, 1999. © 1999 Wiley‐Liss, Inc.

Antiplatelet Is Superior to Anticoagulant Treatment After Coronary Stenting: Fewer Coronary and Other Events Within 30 Days After Stenting

“…A two-tailed p value less than 0.05 was considered statistically significant. (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18) days in group A vs 3 (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16) days in group B, p < 0.000003.…”

Covered Stent to Exclude Intravascular Thrombus

“…1,2 Pharmacological treatment of such lesions includes infusion of intravenous heparin, thrombolytic agents, and more recently, IIb/ IIIa antagonists to prevent the no reflow phenomenon and consequent ischemia. 3 Although peripheral stenting is routinely performed in atherothrombotic lesions, distal embolization remains a potential threat in these situations. 2 With the advent of embolic protection devices, 4 the percutaneous treatment of atherothrombotic lesions has become a safer minimally invasive alternative to surgery.…”